Catalent, CEVEC To Offer Cell Development

Catalent Pharma Solutions and CEVEC Pharmaceuticals have entered a joint commercial cell line development service for pharma and biotech customers worldwide. The offering combines CEVEC’s human cell line, CAP-Technology, with Catalent’s GPEx (Gene Product Expression) Technology to generate high expressing stable human cell lines in a shorter timeframe than traditional methods.

“We are very pleased to be working with Catalent and their truly unique technology to generate stable lines,” said Dr. Rainer Lichtenberger, chief executive officer of CEVEC.

“This exciting collaboration with CEVEC will offer biotech companies developing recombinant proteins and antibodies the advantage of two technologies in one system, enabling them to get a clone candidate in less than five months and significantly reducing their time to clinic,” said Scott Houlton, president, Catalent Development & Clinical Services. “The GPEx technology has been used to express more than 380 different molecules and our integrated development and manufacturing services allow us to take our customers through their clinical trials in the fastest, most cost effective manner.”